Sanofi will acquire clinical-stage biotechnology company, Synthorx, for approximately $2.5 billion.
Synthorx is a California-based biotech focused on prolonging and improving the lives of people with cancer and autoimmune disorders. The company's lead immuno-oncology product candidate, THOR-707, has the potential to become the best-in-class IL-2 therapeutic for the treatment of solid tumors.
Sanofi, which is looking to build its oncology franchise, believes the Synthorx pipeline of engineered lymphokines has promise not only for oncology but also for addressing many autoimmune and inflammatory diseases.
The deal was unanimously approved by both the Sanofi and Synthorx Boards of Directors.
Read the press release
